Category: MS Research Study and Reports

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

August 10, 2026 07:00 ET  | Source: Quantum BioPharma Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study…

Stuart Schlossman

Scientists Find New Evidence Linking Epstein-Barr Virus to MS

July 28, 2026 n 2022, a team at Harvard University provided the strongest evidence to date that the Epstein Barr Virus (EBV)…

Stuart Schlossman

MS Study Alert: How Can We Prevent Falls in People Who Use Wheelchairs? Researchers Recruiting for Two Studies

July 2026 Researchers at the University of Illinois Urbana-Champaign and the University of Illinois Chicago have reported that most people…

Stuart Schlossman

B-Cell Depletion Recruits Protective Gut Cells in MS

July 22, 2026 Summary: Analyzing immune cell profiles across human blood, cerebrospinal fluid (CSF), and intestinal mucosal tissues from control subjects…

Stuart Schlossman

AI Reveals Hidden Gray Matter Lesions in Multiple Sclerosis

Summary: An international team of scientists and clinicians developed a generative artificial intelligence framework that unmasks these previously hidden cortical lesions…

Stuart Schlossman

New research findings challenge old beliefs about myelin repair in MS

Study reveals myelin-making cells are constantly being produced Written by Marisa Wexler, MS Oligodendrocytes, the cells responsible for making myelin, are constantly…

Stuart Schlossman

FDA OKs first human trial of oral MS remyelination therapy PTD802

New US study to evaluate treatment’s safety, tolerability in healthy volunteers Written by Michela Luciano, PhD | June 25, 2026 The U.S. Food…

Stuart Schlossman

FDA clears CTA313 (Car-T Cellular Therapy) trial for progressive MS, autoimmune disease

Basket study will test off-the-shelf CAR T-cell therapy in 3 conditions Written by Patricia Inacio, PhD | June 12, 2026 Imviva Biotech is cleared…

Stuart Schlossman

CMSC 2026: Trial data show frexalimab benefits lasting 3 years

Patients with relapsing disease show stable disability levels Written by Lindsey Shapiro, PhD | June 1, 2026 Three years of treatment with Sanofi’s investigational…

Stuart Schlossman

Key multiple sclerosis models reveal different damage timelines, offering roadmap for myelin repair studies

May 18, 2026 – by University of Notre Dame – edited by Sadie Harley, reviewed by Robert Egan More than…

Stuart Schlossman

Categories

Latest Blog Posts